Trending tickers: Apple, Amazon, Netflix, Reddit and Intensity Therapeutics

Apple (AAPL)

Shares in Apple (AAPL) were higher in pre-market trading following the tech giant's fiscal fourth-quarter results, which exceeded Wall Street's expectations.

Apple posted total revenue of $102.5bn (£77bn) for the quarter, marking an 8% increase year-on-year and surpassing analysts' forecasts. However, iPhone sales, specifically, fell slightly short, coming in at $49bn. Despite this, CEO Tim Cook remained optimistic about the demand for Apple’s (AAPL) latest models.

“We’re not predicting when the supply and demand will balance,” Cook said, acknowledging the supply chain constraints that contributed to the shortfall in iPhone sales. "We’re obviously working very hard to achieve that, because we want to get as many of these products out to customers as possible."

NasdaqGS - Delayed Quote•USD

(AAPL)

Follow View Quote Details

271.40

+1.70

+(0.63%)

At close: October 30 at 4:00:02 PM EDT Advanced Chart

On a more positive note, Cook expressed satisfaction with Apple’s (AAPL) performance in China, where the iPhone 17 received strong reception. “I couldn’t be more pleased with how things are going,” he said, adding that the latest model has resonated well with consumers in the region.

Read more: Stocks to watch next week: Palantir, Advanced Micro Devices, Uber, Novo Nordisk and BP

In terms of profitability, Apple (AAPL) reported net income of $27.46bn for the quarter, a jump from the $14.29bn recorded in the same period last year.

For the fiscal year 2025, Apple (AAPL) achieved total revenue of $416bn, reflecting a 6% increase compared to the previous year. The September quarter alone saw an 8% rise in sales, bolstering investor confidence.

However, Cook also addressed challenges posed by US tariffs, revealing that Apple (AAPL) had incurred a $1.1bn hit from these import duties in the quarter. Looking ahead, Cook warned that the company could face another $1.4bn impact in the holiday quarter, as president Donald Trump’s trade policies continue to impose taxes on foreign goods from countries deemed "unfavourable" to the US economy.

Amazon (AMZN)

Shares in Amazon (AMZN) were up by 12% in pre-market trading, after closing 3% lower on Thursday's session, as its cloud sales reported a 20% growth, topping estimates.

For the third quarter, Amazon (AMZN) reported earnings per share of $1.95, above the $1.57 analysts had expected. Revenue totalled $180.17bn, surpassing the consensus estimate of $177.8bn.

A key driver of this outperformance was Amazon Web Services (AWS), which generated $33bn in revenue, a 20.2% year-over-year increase. This growth exceeded analyst expectations of $32.42 bn and an anticipated 18.1% growth rate. Operating income from AWS rose 9% to $11.4bn, making up about two-thirds of Amazon's (AMZN) total operating profit.

Story Continues

In addition to strong cloud results, Amazon’s (AMZN) advertising segment also exceeded expectations. Ad revenue reached $17.7bn, surpassing the forecasted $17.34bn. This shows the growing importance of Amazon’s advertising business, which continues to be a key contributor to its bottom line.

NasdaqGS - Delayed Quote•USD

(AMZN)

Follow View Quote Details

222.86

-7.44

(-3.23%)

At close: October 30 at 4:00:01 PM EDT Advanced Chart

Looking to the future, Amazon (AMZN) raised its forecast for capital expenditures in 2025, now expecting to spend $125bn, up from an earlier estimate of $118bn. Chief financial officer Brian Olsavsky said that this figure could rise even further in 2026, as the company continues to invest heavily in infrastructure, particularly in its cloud and logistics operations.

For the current quarter, Amazon (AMZN) expects sales to range between $206bn and $213bn, with the midpoint of $209.5bn exceeding analysts’ expectations of $208bn. Operating income for the fourth quarter is projected to fall between $21bn and $26bn, compared with the $23.8bn analysts had forecast.

Netflix (NFLX)

Netflix (NFLX) shares rose 3% in pre-market trading after the streaming giant announced overnight a 10-for-1 stock split, a move that is unlikely to change the company’s fundamentals but could make its high-priced shares more accessible to retail investors.

Under the new plan, existing shareholders as of 10 November will receive nine additional shares for each share they currently hold. These new shares will be distributed on 14 November, and the stock will begin trading at the post-split price on 17 November.

NasdaqGS - Delayed Quote•USD

(NFLX)

Follow View Quote Details

1,089.00

-11.41

(-1.04%)

At close: October 30 at 4:00:00 PM EDT Advanced Chart

Netflix (NFLX), which has seen its stock price surge to over $1,000 per share in recent years, said the decision was designed to "reset the market price of the company’s common stock to a range that will be more accessible to employees who participate in the company’s stock option programme".

Read more: What is a stock split and why are big tech companies opting for it?

While the split doesn't affect the company's overall value, it is seen as a way to make the stock more manageable for both employees and individual investors.

The announcement comes as Netflix's (NFLX) stock has climbed 42% so far this year.

Reddit (RDDT)

Shares in Reddit (RDDT) were 10% higher in pre-market trading after reporting third-quarter earnings on Thursday in which the company beat on the top and bottom and provided strong guidance.

Reddit (RDDT) posted earnings per share of 80 cents, above the 51 cents analysts had forecast. Revenue for the quarter reached $585m, exceeding the $546m estimate. The company’s sales saw a significant 68% year-over-year increase, while net income jumped to $163m, up from just $30m in the same period last year.

Read more: Falling cocoa prices offer sweet relief for chocolate stocks ahead of Halloween

Looking ahead, Reddit (RDDT) guided for fourth-quarter sales between $655m and $665m, above Wall Street’s expectations of $638m. The company also projected adjusted earnings for the quarter to fall between $275m and $285m, topping StreetAccount’s $259m estimate.

NYSE - Delayed Quote•USD

(RDDT)

Follow View Quote Details

194.42

-16.35

(-7.76%)

At close: October 30 at 4:03:48 PM EDT Advanced Chart

Reddit’s (RDDT) global average revenue per user (ARPU) for the third quarter came in at $5.04, surpassing the $4.82 analysts had anticipated. US revenue also outperformed expectations, reaching $480m compared to the expected $445m. International sales amounted to $105m, slightly above the $104m forecasted.

The company’s "other revenue" category, which includes data licensing, rose 7% year-over-year to $36 million, with major partners like Google (GOOG) and OpenAI contributing significantly to this growth.

Stocks: Create your watchlist and portfolio

Reddit (RDDT) also reported a 19% year-over-year increase in global daily active uniques (DAUs) for the third quarter, reaching 116 million, surpassing analyst expectations of 114 million.

In the US, Reddit’s (RDDT) logged-in DAUs grew by 7% year-over-year to 23.1 million, though this growth rate slowed compared to the 12% increase reported in Q2. This marks the fifth consecutive quarter in which the company has seen a deceleration in U.S. logged-in user growth.

Globally, Reddit’s (RDDT) logged-in DAUs rose 14% year-over-year to 50.2 million, while logged-out DAUs grew by 24% to 65.8 million.

Intensity Therapeutics (INTS)

Shares in Intensity Therapeutics (INTS) were in correction territory in pre-market trading, down 38%, after surging by almost 400% the previous session on the back of positive results from a clinical trial.

NasdaqCM - Delayed Quote•USD

(INTS)

Follow View Quote Details

1.3200

+1.0531

+(394.57%)

At close: October 30 at 4:00:02 PM EDT Advanced Chart

The company announced the publication of its Phase 1/2 clinical study data in eBioMedicine, a journal under the Lancet Discovery Science umbrella.

The published manuscript provided details of the safety and efficacy of INT230-6, Intensity Therapeutics’ (INTS) intratumoral therapy designed to treat metastatic or refractory cancers. The study reported a 75% disease control rate and a median overall survival of 11.9 months for heavily pretreated patients with advanced cancer, spanning over 20 different cancer types.

Intensity Therapeutics (INTS) CEO Lewis Bender said: “Given the drug’s mechanism of action and the data reported in this paper from over 20 types of metastatic solid cancers, such as breast, sarcoma, pancreatic, lung, and head and neck, we believe the study results show the potential of INT230-6 to achieve clinical benefit for metastatic patients of multiple cancer types with or without the use of radiation, systemic drugs or immunotherapy.

"As a result, we have initiated randomised controlled studies, including a Phase 3 study in sarcoma.”

Download the Yahoo Finance app, available for Apple and Android.

View Comments